Evaluation of Relapse Presence in Multiple Sclerosis
Evaluation of Relapse Presence in Multiple Sclerosis Patients by Cross-Sectional In-Vivo Corneal Confocal Microscopy
Purpose: This study aims to investigate the demonstrability of increased inflammation and neurodegeneration in multiple sclerosis (MS) patients in relapse period compared to MS patients in remission by cross-sectional analysis of in-vivo corneal confocal microscopy (IVCM), and to evaluate the alternations with a second IVCM administered at least 6 months after the relapse period.
Methods: This prospective, non-randomized-controlled, cross-sectional study included 58 MS patients which were grouped regarding the presence of relapse (MS-Relapse group [n=27] and MS-Control group [n=31]), and age-sex matched 30 healthy controls (HC). The corneal nerve fiber density (CNFD), the corneal nerve branch density (CNBD), the corneal nerve fiber length (CNFL), and dendritic cell (DC) density were evaluated in all MS patients and HCs by IVCM. If the patients in the MS-relapse group did not have an attack within 6 months, the same parameters were evaluated with the second IVCM. The patients with a history of optic neuritis or trigeminal symptoms were excluded.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Istanbul, Turkki, 34899
- Marmara University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Patients for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse
- Patients who were followed up with the diagnosis of RRMS
- Healthy controls
Exclusion Criteria:
- Being younger than 18 years old
- Having any other neurological or metabolic diseases
- Ophthalmological diseases
- A history of optic neuritis and trigeminal symptoms
- Ocular trauma or surgery
- Contact lens use
- The patients who had a relapse attack 6 months prior to the study
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: Case-Control
- Aikanäkymät: Tulevaisuuden
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
MS-Relapse
Twenty-seven patients (MS-Relapse) for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse. The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings These subjects underwent Corneal Confocal Microscopy (IVCM). |
All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany).
Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes.
A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.-
Pharm.
Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM.
For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera.
All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
|
|
MS-Control
Thirty-one patients (MS-Control) who were followed up with the diagnosis of RRMS The diagnosis of RRMS and the new relapse was confirmed and decided by a senior neurologist (K.A) of Marmara University Department of Neurology, according to the revised McDonald criteria, based on clinical and radiological findings. These subjects underwent Corneal Confocal Microscopy (IVCM). |
All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany).
Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes.
A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.-
Pharm.
Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM.
For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera.
All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
|
|
Healthy Controls
Thirty healthy age and gender similar population These subjects underwent Corneal Confocal Microscopy (IVCM).
|
All study subjects underwent IVCM (Rostock Cornea Module, Heidelberg Retinal Tomograph III; Heidelberg Engineering, Germany).
Before the examination, two drops of topical anesthetic with proparacaine hydrochloride (Alcaine 0.5%, Alcon-Couvreur, Belgium) were applied to both eyes.
A carbomer-based gel (Viscotears 0.2%; Dr. Gerhard Mann, Chem.-
Pharm.
Fabrik, Germany) was used as the coupling agent between the cornea and the applanating cap of IVCM.
For correctly positioning the central cornea, all subjects were asked to fixate a determined fixation point and controlled with the device camera.
All scans were performed in approximately 5 minutes for each eye by a single experienced ophthalmologist, masked from the subject's disease status.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Sarveiskalvon hermokuitutiheys (CNFD)
Aikaikkuna: Perustaso
|
CNFD:n analysointiin käytettiin automaattista hermosäikeiden jäljitysohjelmaa - CCMetrics (CCMetrics; M. A. Dabbah, ISBE, Manchesterin yliopisto, Manchester, UK).
|
Perustaso
|
|
Corneal nerve fiber density (CNFD)
Aikaikkuna: 6 Month
|
Automated tracing of nerve fibers program - CCMetrics (CCMetrics; M. A. Dabbah, ISBE, University of Manchester, Manchester, UK) was used to analyze CNFD.
|
6 Month
|
|
Sarveiskalvon hermon haaratiheys (CNBD)
Aikaikkuna: Perustaso
|
CNBD:n analysointiin käytettiin automaattista hermosäikeiden jäljitysohjelmaa - CCMetrics (CCMetrics; M. A. Dabbah, ISBE, Manchesterin yliopisto, Manchester, UK).
|
Perustaso
|
|
Corneal nerve branch density (CNBD)
Aikaikkuna: 6 Month
|
Automated tracing of nerve fibers program - CCMetrics (CCMetrics; M. A. Dabbah, ISBE, University of Manchester, Manchester, UK) was used to analyze CNBD.
|
6 Month
|
|
Corneal nerve fiber length (CNFL)
Aikaikkuna: Baseline
|
Automated tracing of nerve fibers program - CCMetrics (CCMetrics; M. A. Dabbah, ISBE, University of Manchester, Manchester, UK) was used to analyze CNFL.
|
Baseline
|
|
Corneal nerve fiber length (CNFL)
Aikaikkuna: 6 Months
|
Automated tracing of nerve fibers program - CCMetrics (CCMetrics; M. A. Dabbah, ISBE, University of Manchester, Manchester, UK) was used to analyze CNFL.
|
6 Months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Dendritic Cells
Aikaikkuna: Baseline
|
the number of DCs counted by ImageJ's Cell Counter plug-in
|
Baseline
|
|
Dendritic Cells
Aikaikkuna: 6 Months
|
the number of DCs counted by ImageJ's Cell Counter plug-in
|
6 Months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Hermoston sairaudet
- Immuunijärjestelmän sairaudet
- Demyelinisoivat autoimmuunisairaudet, keskushermosto
- Hermoston autoimmuunisairaudet
- Demyelinisoivat sairaudet
- Autoimmuunisairaudet
- Sairauden ominaisuudet
- Multippeliskleroosi
- Skleroosi
- Multippeliskleroosi, uusiutuva-remitoiva
- Toistuminen
Muut tutkimustunnusnumerot
- 09.2021.240
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .